The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: Latest findings and clinical potential

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 1, 2013, Pages 3-11

  Cutolo, Maurizio ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

biological disease modifying antirheumatic drug (DMARD); Janus kinase inhibitors; kinases; rheumatoid arthritis; therapy for rheumatoid arthritis

Indexed keywords

ADALIMUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 3; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLACEBO; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; BINDING AFFINITY; BINDING SITE; BRONCHITIS; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME ACTIVITY; FEMUR FRACTURE; FOOT MALFORMATION; HEART FAILURE; HIP OSTEOARTHRITIS; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LUNG TUBERCULOSIS; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84878345601     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12470753     Document Type: Review

References (37)

1. Buckley R. Schiff R. Schiff S. Markert M. Williams L. Harville T. et al. (1997) Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130: 378–387.
2. Cohen S. Cheng T. Chindalore V. Damjanov N. Burgos-Vargas R. Delora P. et al. (2009) Evaluation of the efficacy and safety of pamapimod, a p 38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60: 335–344.
3. Cuevas B. Abell A. Johnson G. (2007) Role of mitogen-activated protein kinase kinase kinases in signal integration. Oncogene 26: 3159–3171.
4. Cutolo M. (2011) Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol 7: 500–502.
5. Damjanov N. Kauffman R. Spencer-Green G. (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p 38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60: 1232–1241.
6. Davis M. Hunt J. Sanna Herrgard S. Ciceri P. Wodicka L. Pallares G. et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046–1051.
7. Emery P. Dörner T. (2011) Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 70: 2063–2070.
8. Fleischmann R. (2012) Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 24: 335–341.
9. Fleischmann R. Cutolo M. Genovese M. Lee E. Kanik K. Sadis S. et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64: 617–629.
10. Fleischmann R. Kremer J. Cush J. Schulze-Koops H. Connell C.A. Bradley J.D. et al. (2012) ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367: 495–507.
11. Genovese M. Kavanaugh A. Weinblatt M. Peterfy C. DiCarlo J. White M. et al. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 63: 337–345.
12. Ghoreschi K. Jesson M. Li X. Lee J. Ghosh S. Alsup J. et al. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186: 4234–4243.
13. Ghoreschi K. Laurence A. O'Shea J. (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10: 356–360.
14. Guma M. Hammaker D. Topolewski K. Corr M. Boyle D. Karin M. et al. (2012) Anti-inflammatory functions of the p 38 pathway in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK3 or MKK6. Arthritis Rheum 2012 64: 2887–2895.
15. Karaman M. Herrgard S. Treiber D. Gallant P. Atteridge C. Campbell B. et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127–132.
16. Kawamura M. McVicar D. Johnston J. Blake T. Chen Y. Lal B. et al. (1994) Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 91: 6374–6378.
17. Kremer J. Bloom B. Breedveld F. Coombs J. Fletcher M. Gruben D. et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895–1905.
18. Kremer J. Cohen S. Wilkinson B. Connell C. French J. Gomez-Reino J. et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64: 970–981.
19. Leah E. (2012) Clinical trials: Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis. Nat Rev Rheumatol 2012 Aug 28. doi: 10.1038/nrrheum.2012.145 [Epub ahead of print].
20. Leonard W. (2001) Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73: 271–277.
21. Leonard W. Lin J. (2000) Cytokine receptor signaling pathways. J Allergy Clin Immunol 105: 877–888.
22. Leonard W. O'Shea J. (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293–322.
23. McInnes I. O'Dell J. (2010) Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel therapeutics - exciting gifts but how best to use them? Best Pract Res Clin Rheumatol 24: 441–442.
24. McInnes I. Schett G. (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205–2219.
25. O'Shea J. Pesu M. Borie D. Changelian P. (2004) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 3: 555–564
26. Pesu M. Candotti F. Husa M. Hofmann S. Notarangelo L. O'Shea J. (2005) Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 203: 127–142.
27. Pesu M. O'Shea J. Hennighausen L. Silvennoinen O. (2005) Identification of an acquired mutation in Jak 2 provides molecular insights into the pathogenesis of myeloproliferative disorders. Mol Interv 5: 211–215.
28. Riese R. Krishnaswami S. Kremer J. (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24: 513–526.
29. Scott D. (2011) Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. Drugs 71: 1121–1132.
30. Tanaka Y. Suzuki M. Nakamura H. Toyoizumi S. Zwillich S. (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Tofacitinib Study Investigators. Arthritis Care Res 63: 1150–1158.
31. Trujillo J. (2011) MEK inhibitors: a patent review 2008–2010. Expert Opin Ther Pat 21: 1045–1046.
32. van Vollenhoven R. Fleischmann R. Cohen S. Lee E. García Meijide J. Wagner S. et al. ORAL Standard Investigators. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367: 508–519.
33. Weinblatt M. Kavanaugh A. Burgos-Vargas R. Dikranian A. Medrano-Ramirez G. Morales-Torres J. et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309–3318.
34. Weinblatt M. Kavanaugh A. Genovese M. Peterfy C. DiCarlo J. White M. et al. (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363: 1303–1312.
35. Wolfe F. Michaud K. (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large United States observational study. Arthritis Rheum 56: 2886–2895.
36. Vosshenrich C. Di Santo J. (2002) Interleukin signaling. Curr Biol 12: R760–R763
37. Yamaoka K. Saharinen P. Pesu M. Holt V. III Silvennoinen O. O'Shea J. et al. (2004) The Janus kinases (JAKs). Genome Biol 5: 253–257.